An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate blood level profiles of multiple oral doses of
AP09004 vs. active control and to determine its safety and efficacy in Parkinson's patients.
Phase:
Phase 2
Details
Lead Sponsor:
Intec Pharma Ltd.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa